Ponciano D. Cruz

Learn More
A major barrier to successful cancer immunotherapy is the tumor's ability to induce T-cell tolerance by exploiting host regulatory mechanisms. Having discovered the DC-HIL receptor, which inhibits T-cell responses by binding to syndecan-4 on effector T cells, we posited the DC-HIL/syndecan-4 pathway to have an important role in cancer promotion. Among(More)
Melanoma growth and metastasis depend on a battle between the cancer's invasive properties and the host's capacity to counter such attributes. Immunosuppression is a potent promoter of cancer progression that not only counters host control of tumor spread but also prevents anti-cancer treatments from achieving their full benefit (Ilkovitch and Lopez, 2008).(More)
  • 1